Dianthus Therapeutics Inc
dianthustx.comDianthus Therapeutics Inc (NASDAQ: DNTH) is a clinical-stage biopharmaceutical company developing antibody-based therapies targeting complement-mediated diseases. The company generates no product revenue and funds operations through cash and investment holdings, having recorded $15.6 million in other income (primarily interest income) for the year ended December 31, 2025. Its two lead programs are claseprubart, which is in Phase 2 and Phase 3 clinical trials, and DNTH212, which is in earlier-stage development. General and administrative expenses were $34.3 million for the year ended December 31, 2025, up from $25.0 million for the year ended December 31, 2024. Research and development activities are conducted in collaboration with third-party contract research organizations, including a milestone-based agreement with IONTAS Limited carrying potential payments of up to approximately $7.3 million, and a license agreement with Alloy Therapeutics carrying potential payments of up to $12.8 million for the claseprubart program. Dianthus also holds a collaboration with Tenacia for claseprubart. Ryan Savitz serves as Executive Vice President, Chief Financial Officer, and Chief Business Officer as of the 10-K filed March 9, 2026.
Products & Services
Claseprubart: antibody therapy in Phase 2 and Phase 3 clinical trials for complement-mediated diseases (as of 10-K filed March 9, 2026). DNTH212: earlier-stage antibody product candidate. Both are pre-commercial.
Revenue Model
No product revenue as of the 10-K filed March 9, 2026. Operations are funded by cash reserves and short- and long-term investments, with interest income the primary source of other income ($15.6 million for the year ended December 31, 2025). Future revenue, if any, would depend on regulatory approval and commercialization of claseprubart or DNTH212, or milestone and royalty payments from partners.
Customers & Markets
No commercial customers as of the 10-K filed March 9, 2026. Target end markets are patients with complement-mediated diseases. Third-party payors, hospitals, and regional healthcare authorities are identified as future relevant parties for drug access and pricing.
Geographic Exposure
Primarily United States-based operations. Subject to regulatory requirements in other jurisdictions for clinical trials and potential future commercialization, per the 10-K filed March 9, 2026. No specific non-U.S. revenue or operational footprint disclosed.
Financial Snapshot
Loading...
